Overview

Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To test whether treatment with the angiotensin II receptor antagonist Irbesartan improves insulin sensitivity and metabolic profile in patients with chronic heart failure.
Phase:
Phase 4
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborator:
Bristol-Myers Squibb
Treatments:
Angiotensin Receptor Antagonists
Insulin
Irbesartan